Welcome to our dedicated page for CervoMed SEC filings (Ticker: CRVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CervoMed Inc. (NASDAQ: CRVO) SEC filings, offering a detailed view of how the clinical-stage biotechnology company reports its operations, financial condition, and development plans for neflamapimod and related programs. As a NASDAQ Capital Market issuer, CervoMed files current reports on Form 8-K, annual reports on Form 10-K, and other documents that outline its progress in dementia with Lewy bodies (DLB) and other age-related brain disorders.
In recent Form 8-K filings, CervoMed has furnished press releases covering quarterly financial results, new clinical data from the Phase 2b RewinD-LB trial, and written feedback from the U.S. Food and Drug Administration on the design of its planned Phase 3 trial in DLB. These filings describe how the company plans to use endpoints such as change in Clinical Dementia Rating – Sum of Boxes (CDR-SB), enrichment strategies based on plasma ptau181, and biomarker assessments like glial fibrillary acidic protein (GFAP) to support a potential New Drug Application for neflamapimod.
Other 8-Ks document corporate governance events, including the appointment of new directors and executive officers, adoption of equity incentive plans, and stock option grants. Filings relating to the annual meeting of stockholders detail voting outcomes on director elections, auditor ratification, advisory votes on executive compensation, and approval of equity plans. Together, these documents provide a structured record of CervoMed’s governance, capital structure, and incentive arrangements.
Through Stock Titan, users can review these SEC filings alongside AI-powered summaries that explain key sections in plain language. Real-time updates from EDGAR help surface new 8-Ks, 10-Qs, and 10-Ks as they are filed, while AI-generated highlights can point to important disclosures on clinical trial results, regulatory milestones, grant funding, and risk factors. Investors can also use the filings page to monitor how CervoMed describes its lead program, neflamapimod, and its broader strategy in age-related brain disorders over time.
CervoMed Director Jane H. Hollingsworth received a stock option grant following her election to the company's board of directors at the 2025 Annual Meeting of Stockholders. The transaction details include:
- Grant of options to purchase 8,100 shares of common stock
- Exercise price set at $6.52 per share
- Options granted on June 23, 2025 with expiration on June 23, 2035
- Vesting schedule: Monthly over one year in equal 1/12th increments
- Vesting begins June 30, 2025, subject to continued service
The stock options were granted under the company's 2025 Equity Incentive Plan in accordance with their non-employee director compensation policy. The Form 4 was filed by William R. Elder as attorney-in-fact for Hollingsworth.
CervoMed Director and 10% owner Sylvie Gregoire received a stock option grant following her election to the company's board of directors at the 2025 Annual Meeting of Stockholders. The transaction details include:
- Grant of options to purchase 8,100 shares of common stock
- Exercise price set at $6.52 per share
- Options granted on June 23, 2025 with expiration on June 23, 2035
- Vesting schedule: Monthly over one year in equal 1/12th increments starting June 30, 2025
- Grant made under the company's 2025 Equity Incentive Plan per non-employee director compensation policy
The options are subject to continued service through applicable vesting dates. The filing was signed by William R. Elder as attorney-in-fact for Gregoire on June 25, 2025.